Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Studies Of Clolar, Neulasta, Kepivance To Be Discussed By Oncology Subcommittee

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme and Amgen will share their challenges in design and implementation of post-marketing pediatric studies, such as patient accrual problems and changes in standard of care, at FDA's Oncologic Drugs Advisory Committee on Oct. 20.

You may also be interested in...



Genzyme Clolar Confirmatory Pediatric Study Should Enroll Early Relapse Leukemia Patients, Cmte. Says

Focus on earlier stage disease would enlarge potential pediatric population for study. FDA’s Oncology Pediatric Subcommittee also recommends that primary trial endpoints include remission induction rate.

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue

Topics

UsernamePublicRestriction

Register

PS061120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel